Comment on the Paper by Su et al. Entitled ‘Safety and Efficacy of Warfarin plus Aspirin Combination Therapy for Giant Coronary Artery Aneurysm Secondary to Kawasaki Disease: A Meta-Analysis'

Loomba, Rohit S.

doi:10.1159/000369879

Cited by 2 publications

(3 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the acute stage of KD children, as was given 30~50mg/(kg.d) orally 2~3 times and changed to 3 5mg/(kg.d) in 48-72h or 14 days after the onset of fever, and maintained in one dose. [30][31][32][33] As KD's acute phase often appears to be a persistent high fever, clinical use of ibuprofen can reduce fever. Ibuprofen combined with ibuprofen can counteract the irreversible platelet inhibition induced by Asp, so ibuprofen should be avoided for fever reduction in children with CAL, and acetaminophen can be used for fever reduction.…”

Section: Bmentioning

confidence: 99%

Consensus Committee of experts on Kawasaki Disease and Chinese Journal of Contemporary Pediatrics – the expert consensuses on intravenous immunoglobulin, aspirin, and glucocorticoid

Ren,

Deng,

et al. 2024

Eur J Clin Exp Med

View full text Add to dashboard Cite

Introduction and aim. Kawasaki disease (KD) is an acute vasculitis with unknown etiology, usually occurring in chil dren under 5 years old. This article will summarize the three consensuses formulated in China about KD. Material and methods. English databases for consensus search include UpToDate, BMJ Clinical Evidence, National Guideline Clearinghouse, Joanna Briggs Institute Library, Cochrane Library, and PubMed, etc.; Chinese databases in clude China Biomedical Literature Service, China Knowledge Network, Wanfang database, etc. All literature searches ended on February 28, 2022. Analysis of the literature. KD is a common acquired heart disease in children and can lead to severe complications such as coronary injury. However, intravenous immunoglobulin (IVIG) combined with oral aspirin (Asp) is currently recognized as the most effective treatment in KD acute stage and the first-line treatment to prevent cardiovascular complications. Glucocorticoid (GC) is mainly used for KD patients with a high risk of coronary artery aneurysm (CAA), no immunoglobulin response, and confirmed CAA. There are already consensus guidelines on diagnosing and treat ing KD in different countries. This article summarizes the relevant expert consensus on aspirin, glucocorticoids and IVIG for the treatment of Kawasaki disease in China. Conclusion. Still, there are inconsistent opinions in the literature on the mechanism, optimal timing, and dosage of medication for KD.

show abstract

Section: Bmentioning

confidence: 99%

Consensus Committee of experts on Kawasaki Disease and Chinese Journal of Contemporary Pediatrics – the expert consensuses on intravenous immunoglobulin, aspirin, and glucocorticoid

Ren,

Deng,

et al. 2024

Eur J Clin Exp Med

View full text Add to dashboard Cite

show abstract

“…We would like to thank Dr. Loomba [1] for his interest in our study [2] and appreciate his insights and comments. It has given us the opportunity to recheck our work.…”

mentioning

confidence: 99%

“…As shown in the last line of table 1 in the original study, only 11 of the 13 patients had had at least 1 giant CAA. Here at least we did not make the mistake of ‘extracting data for the number of males instead of for the overall patient number' [1]. …”

mentioning

confidence: 99%